HOUSE FILE 2492 BY COMMITTEE ON COMMERCE

(SUCCESSOR TO HF 2157)

A BILL FOR

An Act relating to insurance coverage for biomarker testing.
 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:

H.F. 2492

1 Section 1. <u>NEW SECTION</u>. 514C.36 Biomarker testing — 2 coverage.

3 l. As used in this section, unless the context otherwise 4 requires:

5 a. "Biomarker" means a characteristic that is objectively 6 measured and evaluated as an indicator of normal biological 7 processes, pathogenic processes, or pharmacologic responses to 8 a specific therapeutic intervention, including but not limited 9 to genetic mutations or protein expression.

10 b. "Biomarker testing" means the analysis of an individual's 11 tissue, blood, or other biospecimen for the presence of a 12 biomarker, including but not limited to single-analyte tests, 13 multiplex panel tests, or whole genome sequencing.

14 c. "Clinical utility" means sufficient medical and 15 scientific evidence indicating the use of a specific biomarker 16 test will provide meaningful information that will affect 17 treatment decisions and improve a covered person's outcome.

18 *d. Consensus statement* means a statement developed by 19 an independent, multidisciplinary panel of experts, none of 20 whom have a conflict of interest, who utilize a transparent 21 methodology and reporting structure. A consensus statement 22 concerns specific clinical circumstances and is based on the 23 best available evidence for the purpose of optimizing the 24 outcomes of clinical care.

e. "Covered person" means a policyholder, subscriber, or other person participating in a policy, contract, or plan that provides for third-party payment or prepayment of health or medical expenses.

29 f. "Health care professional" means the same as defined in 30 section 514J.102.

31 g. "Local coverage determinations" means the same as defined 32 in section 1869(f)(2)(B) of the federal Social Security Act. 33 h. "National coverage determinations" means the same as 34 defined in section 1869(f)(1)(B) of the federal Social Security 35 Act.

LSB 6095HV (3) 90

nls/ko

-1-

1/4

H.F. 2492

i. "Nationally recognized clinical practice guidelines"
means evidence-based clinical practice guidelines developed by
independent organizations or medical professional societies,
none of which have a conflict of interest, that utilize a
transparent methodology and reporting structure. Clinical
practice guidelines establish standards of care informed
by a systematic review of evidence and assessment of the
costs and benefits of alternative care options and include
recommendations intended to optimize patient care.

10 2. Notwithstanding the uniformity of treatment requirements 11 of section 514C.6, a policy, contract, or plan providing for 12 third-party payment or prepayment of medical expenses shall 13 provide coverage for biomarker testing for the purposes of 14 diagnosing, treating, appropriately managing, or monitoring a 15 disease or condition in a covered person when the biomarker 16 testing has demonstrated clinical utility, including but not 17 limited to any of the following:

18 a. Labeled indications for a test approved or cleared by
19 the United States food and drug administration or indicated
20 tests for a drug approved by the United States food and drug
21 administration.

b. Centers for Medicare and Medicaid services of the
 United States department of health and human services national
 coverage determinations or Medicare administrative contractor
 local coverage determinations.

26 c. Nationally recognized clinical practice guidelines and27 consensus statements.

3. Coverage required under this section shall limit of disruptions in care, including mitigating the need for a covered person to undergo multiple biopsies or to provide al multiple biospecimen samples.

32 4. A covered person and the covered person's health care 33 professional shall have access to a clear and convenient 34 process available on the health carrier's internet site to 35 request an exception to coverage provided under this section.

-2-

LSB 6095HV (3) 90 nls/ko 5. a. This section applies to the following classes of
 2 third-party payment provider policies, contracts, or plans
 3 delivered, issued for delivery, continued, or renewed in this
 4 state on or after January 1, 2025:

5 (1) Individual or group accident and sickness insurance6 providing coverage on an expense-incurred basis.

7 (2) An individual or group hospital or medical service 8 contract issued pursuant to chapter 509, 514, or 514A.

9 (3) An individual or group health maintenance organization 10 contract regulated under chapter 514B.

11 (4) A plan established pursuant to chapter 509A for public 12 employees.

13 b. This section shall apply to all of the following:

14 (1) The medical assistance program under chapter 249A.

15 (2) The healthy and well kids in Iowa (Hawki) program under 16 chapter 514I.

17 (3) A managed care organization acting pursuant to a 18 contract with the department of health and human services under 19 chapter 249A, or with the healthy and well kids in Iowa (Hawki) 20 program under chapter 514I.

21 c. This section shall not apply to accident-only,
22 specified disease, short-term hospital or medical, hospital
23 confinement indemnity, credit, dental, vision, Medicare
24 supplement, long-term care, basic hospital and medical-surgical
25 expense coverage as defined by the commissioner, disability
26 income insurance coverage, coverage issued as a supplement
27 to liability insurance, workers' compensation or similar
28 insurance, or automobile medical payment insurance.

29 6. The commissioner of insurance may adopt rules pursuant to30 chapter 17A to administer this section.

31

EXPLANATION

32 The inclusion of this explanation does not constitute agreement with 33 the explanation's substance by the members of the general assembly.

34 This bill relates to health insurance coverage for biomarker 35 testing.

LSB 6095HV (3) 90

3/4

nls/ko

-3-

1 The bill defines "biomarker testing" as an analysis of 2 an individual's tissue, blood, or other biospecimen for the 3 presence of a biomarker. "Biomarker" is also defined in the 4 bill.

5 The bill requires a health carrier that offers individual, 6 group, or small group contracts, policies, or plans in this 7 state that provide for third-party payment or prepayment of 8 health or medical expenses to offer coverage for biomarker 9 testing for purposes of diagnosing, treating, appropriately 10 managing, or monitoring a disease or condition in a covered 11 person when the test has demonstrated clinical utility as 12 detailed in the bill. "Clinical utility" is defined in the 13 bill. Coverage shall be provided in a manner which limits 14 disruptions in a person's care. The bill requires a health 15 carrier to provide a process on its internet site for a person 16 and the person's health care professional to seek an exception 17 to coverage required under the bill.

The bill applies to third-party payment provider contracts, policies, or plans delivered, issued for delivery, continued, or renewed in this state on or after January 1, 2025, by the third-party payment providers enumerated in the bill. The bill specifies the types of specialized health-related insurance which are not subject to the bill's coverage requirements. The bill applies to the medical assistance program under Code chapter 249A, the healthy and well kids in Iowa (Hawki) program under Code chapter 514I, and a managed care organization acting pursuant to a contract with the department sof health and human services to administer either the medical assistance program.

30 The commissioner of insurance may adopt rules to administer 31 the bill.

-4-

LSB 6095HV (3) 90 nls/ko